Literature DB >> 10964494

Cyclosporin A enhances survival, ameliorates brain damage, and prevents secondary mitochondrial dysfunction after a 30-minute period of transient cerebral ischemia.

P A Li1, T Kristián, Q P He, B K Siesjö.   

Abstract

Cyclosporin A (CsA) has been shown to be efficacious in protecting against ischemic injury after short periods (5 to 10 min) of forebrain ischemia. The present experiments were undertaken to study if a long period of forebrain ischemia (30 min), induced at a brain temperature of 37 degrees C, is compatible with survival and if the brain damage incurred can be ameliorated by CsA. The results showed that animals subjected to 30 min of forebrain ischemia at a brain temperature of 37 degrees C failed to survive after the first 24 h of recovery and showed extensive neuronal necrosis in all selectively vulnerable regions after 1 day of survival. CsA, when injected in combination with an intracerebral lesion to open the blood-brain barrier, markedly prolonged the survival time. CsA-injected animals also showed amelioration of histological lesions, an effect that was sustained for at least 4 days. Experiments with mitochondria isolated from the neocortex and hippocampus showed that state 3 respiratory rates decreased during ischemia, recovered after 1 and 3 h of recirculation, and then showed a secondary decline at 6 h. Administration of CsA prevented this secondary decline. Measurements of neocortical cerebral blood flow showed that there was no secondary hypoperfusion prior to secondary mitochondrial dysfunction, implying that changes in blood flow may not be responsible for the rapidly developing, secondary brain damage. The results thus demonstrate that if brain temperature is upheld at 37 degrees C, a 30-min period of ischemia is not compatible with survival after the first day of recovery, and gross histopathological damage develops within that period. CsA was efficacious in prolonging animal survival, ameliorating brain damage, and preventing the secondary mitochondrial dysfunction. Since CsA blocks the mitochondrial permeability transition pore its action may, at least in part, be on mitochondrial integrity and function. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964494     DOI: 10.1006/exnr.2000.7459

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

1.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

Review 2.  Targeting mitochondrial function for the treatment of acute spinal cord injury.

Authors:  Melanie L McEwen; Patrick G Sullivan; Alexander G Rabchevsky; Joe E Springer
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Cyclophilin-A is involved in excitotoxin-induced caspase activation in rat neuronal B50 cells.

Authors:  Michela Capano; Sukaina Virji; Martin Crompton
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

4.  Combination Treatment with Methylene Blue and Hypothermia in Global Cerebral Ischemia.

Authors:  Lei Li; Rongli Yang; Pingjing Li; Hailong Lu; Jingbo Hao; Liyan Li; Donovan Tucker; Quanguang Zhang
Journal:  Mol Neurobiol       Date:  2017-03-07       Impact factor: 5.590

Review 5.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  Effects of FK506 and cyclosporin a on calcium ionophore-induced mitochondrial depolarization and cytosolic calcium in astrocytes and neurons.

Authors:  Sibel Kahraman; Linda L Bambrick; Gary Fiskum
Journal:  J Neurosci Res       Date:  2011-07-11       Impact factor: 4.164

7.  Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation.

Authors:  Angélique Deleersnijder; Anne-Sophie Van Rompuy; Linda Desender; Hans Pottel; Luc Buée; Zeger Debyser; Veerle Baekelandt; Melanie Gerard
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

8.  Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet.

Authors:  Todd J Kilbaugh; Sunita Bhandare; David H Lorom; Manda Saraswati; Courtney L Robertson; Susan S Margulies
Journal:  J Neurotrauma       Date:  2011-04-12       Impact factor: 5.269

9.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

Review 10.  Stem cells: implications in experimental ischaemic stroke therapy.

Authors:  Ashish K Rehni; Inderbir Singh; Nirmal Singh; Manoj Kumar
Journal:  Stem Cell Rev       Date:  2008-05-31       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.